The Combination of Olaratumab with Doxorubicin and Cisplatinum Regresses a Chemotherapy-Resistant Osteosarcoma in a Patient-Derived Orthotopic Xenograft Mouse Model.
Journal
Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
10
05
2019
revised:
10
06
2019
accepted:
17
06
2019
pubmed:
13
7
2019
medline:
13
7
2019
entrez:
13
7
2019
Statut:
ppublish
Résumé
Chemotherapy-resistant osteosarcoma is a recalcitrant disease. It is a frequent cause of death to the patients who are usually adolescent or young adults. The goal of the present study was to determine the efficacy of the combination of olaratumab (OLA), doxorubicin (DOX), and cisplatinum (CDDP) on osteosarcoma, which is resistant to first-line therapy, in a patient-derived orthotopic xenograft (PDOX) model. The osteosarcoma PDOX model was randomized into six treatment groups of six mice: control; CDDP alone; DOX and CDDP; OLA + DOX; OLA + CDDP; and OLA + DOX and CDDP. Tumor size and body weight were measured during 14 days of treatment. Tumor growth was regressed only by the treatment with a combination of OLA + DOX and CDDP. Tumors treated with this three-drug combination had the most tumor necrosis and the lowest Ki-67 index. The present study demonstrates the power of the PDOX model to identify novel effective treatment strategy for chemotherapy-resistant osteosarcoma.
Identifiants
pubmed: 31299622
pii: S1936-5233(19)30233-5
doi: 10.1016/j.tranon.2019.06.002
pmc: PMC6624322
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1257-1263Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Mol Cancer Ther. 2005 Mar;4(3):369-79
pubmed: 15767546
J Clin Oncol. 2005 Jun 1;23(16):3742-51
pubmed: 15923571
Cancer Treat Rev. 2006 Oct;32(6):423-36
pubmed: 16860938
Cancer Res. 2012 Sep 1;72(17):4515-25
pubmed: 22787122
Cancer Res. 2013 Apr 1;73(7):2139-49
pubmed: 23338608
Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604
pubmed: 24452395
Cytokine Growth Factor Rev. 2014 Jun;25(3):273-83
pubmed: 24703957
Cancer Sci. 2014 Jul;105(7):862-9
pubmed: 24816152
Nat Rev Cancer. 2015 Aug;15(8):451-2
pubmed: 26422835
Lancet. 2016 Jul 30;388(10043):488-97
pubmed: 27291997
Rheumatol Ther. 2016 Dec;3(2):221-243
pubmed: 27761754
Ann Oncol. 2017 Mar 1;28(3):541-546
pubmed: 28426120
Cell Cycle. 2017 Jun 18;16(12):1164-1170
pubmed: 28494180
Ann Pharmacother. 2017 Dec;51(12):1090-1098
pubmed: 28778132
Lung Cancer. 2017 Sep;111:108-115
pubmed: 28838379
Clin Cancer Res. 2018 Feb 15;24(4):847-857
pubmed: 29191969
Eur J Cancer. 2018 Mar;92:33-39
pubmed: 29413687
SICOT J. 2018;4:12
pubmed: 29629690
J Oncol Pharm Pract. 2019 Mar;25(2):442-448
pubmed: 30032714
Clin Sarcoma Res. 2018 Aug 2;8:15
pubmed: 30083310
Anticancer Res. 2018 Oct;38(10):5639-5644
pubmed: 30275182
Cancer Sci. 2018 Dec;109(12):3962-3970
pubmed: 30353601
Biochem Biophys Res Commun. 2018 Dec 2;506(4):912-917
pubmed: 30392912
Eur J Cancer. 2019 Jan;107:186-195
pubmed: 30573277
BMC Cancer. 2018 Dec 27;18(1):1292
pubmed: 30591028
Cancer Discov. 2019 Mar;9(3):312-313
pubmed: 30696623
Cancer Chemother Pharmacol. 2019 May;83(5):809-815
pubmed: 30758647
J Natl Cancer Inst. 2019 Feb 21;:null
pubmed: 30793158
Cancer Lett. 2019 Jun 1;451:122-127
pubmed: 30867142
Cancer Chemother Pharmacol. 2019 Jun;83(6):1075-1082
pubmed: 30929053